1. Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids.
- Author
-
Tarjus A, Martínez-Martínez E, Amador C, Latouche C, El Moghrabi S, Berger T, Mak TW, Fay R, Farman N, Rossignol P, Zannad F, López-Andrés N, and Jaisser F
- Subjects
- Acute-Phase Proteins deficiency, Acute-Phase Proteins genetics, Acute-Phase Proteins pharmacology, Aldosterone blood, Animals, Aorta drug effects, Aorta pathology, Cardiomyopathy, Hypertrophic chemically induced, Cardiomyopathy, Hypertrophic physiopathology, Cells, Cultured, Cytokines biosynthesis, Cytokines genetics, Female, Fibroblasts, Fibrosis, Galectin 3 biosynthesis, Galectin 3 blood, Galectin 3 genetics, Humans, Hypertension physiopathology, Hypertrophy, Kidney pathology, Lipocalin-2, Lipocalins blood, Lipocalins genetics, Lipocalins pharmacology, Male, Mice, Myocardium cytology, Myocardium metabolism, Myocytes, Smooth Muscle drug effects, Myocytes, Smooth Muscle physiology, Nephrectomy adverse effects, Obesity, Abdominal blood, Oncogene Proteins deficiency, Oncogene Proteins genetics, Peptide Fragments blood, Procollagen blood, Proto-Oncogene Proteins blood, Proto-Oncogene Proteins pharmacology, Rats, Recombinant Proteins pharmacology, Acute-Phase Proteins physiology, Aldosterone toxicity, Lipocalins physiology, Obesity, Abdominal physiopathology, Oncogene Proteins physiology, Proto-Oncogene Proteins physiology
- Abstract
Activation of the mineralocorticoid receptor has been shown to be deleterious in cardiovascular diseases (CVDs). We have recently shown that lipocalin 2 (Lcn2), or neutrophil gelatinase-associated lipocalin (NGAL), is a primary target of aldosterone/mineralocorticoid receptor in the cardiovascular system. Lcn2 is a circulating protein, which binds matrix metalloproteinase 9 and modulates its stability. We hypothesized that Lcn2 could be a mediator of aldosterone/mineralocorticoid receptor profibrotic effects in the cardiovascular system. Correlations between aldosterone and profibrotic markers, such as procollagen type I N-terminal peptide, were investigated in healthy subjects and subjects with abdominal obesity. The implication of Lcn2 in the mineralocorticoid pathway was studied using Lcn2 knockout mice subjected to a nephrectomy/aldosterone/salt (NAS) challenge for 4 weeks. In human subjects, NGAL/matrix metalloproteinase 9 was positively correlated with plasma aldosterone and fibrosis biomarkers. In mice, loss of Lcn2 prevented the NAS-induced increase of plasma procollagen type I N-terminal peptide, as well as the increase of collagen fibers deposition and collagen I expression in the coronary vessels and the aorta. The lack of Lcn2 also blunted the NAS-induced increase in systolic blood pressure. Ex vivo, treatment of human fibroblasts with recombinant Lcn2 induced the expression of collagen I and the profibrotic galectin-3 and cardiotrophin-1 molecules. Our results showed that Lcn2 plays a key role in aldosterone/mineralocorticoid receptor-mediated vascular fibrosis. The clinical data indicate that this may translate in human patients. Lcn2 is, therefore, a new biotarget in cardiovascular fibrosis induced by mineralocorticoid activation., (© 2015 American Heart Association, Inc.)
- Published
- 2015
- Full Text
- View/download PDF